Unveiling the Spectrum of Glucose Variability: A Novel Perspective on FreeStyle Libre Monitoring Data.
Continuous glucose monitoring
Glucose variability
Glycated haemoglobin (HbA1c)
Type 1 diabetes (T1D)
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
received:
20
06
2024
accepted:
30
08
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
23
10
2024
Statut:
aheadofprint
Résumé
Since the introduction of insulin therapy, it has become apparent that type 1 diabetes (T1D) is accompanied by long-term microvascular and macrovascular complications. In the context of the many benefits of continuous glucose monitoring (CGM), there remain opportunities to study the large amount of data now available in order to maximise its potential in the endeavour to reduce the occurrence of diabetes tissue complications in the longer term. Continuous glucose monitoring values were downloaded for 89 type 1 diabetes mellitus (T1D) individuals for up to 18 months from 2021 to 2023. Data for patient demographics was also taken from the patient record which included Sex, Date of Birth, and Date of Diagnosis. The recorded laboratory glycated haemoglobin (HbA1c) test results were also recorded. The glucose management index (GMI) was calculated from average glucose readings for 18 months using the formula GMI (%) = (0.82 - (Average glucose/100)). This was then adjusted to give GMI (mmol/mol) = 10.929 * (GMI (%) - 2.15). Average Glucose Fluctuation (AGF) was calculated by adding up the total absolute change value between all recorded results over 18 months and dividing by the number of results minus one. The % Above Critical Threshold (ACT) was calculated by summing the total number of occurrences for each result value. A cumulative 95% limit was then applied to identify the glucose value that only 5% of results exceeded in the overall population. Using this value, we estimated the percentage of total tests that were above the Critical Threshold (ACT). The mean age of the participants was 42.6 years, and the mean duration of T1D was 18.4 years. A total of 3.22 million readings were analysed, yielding an average blood glucose level of 10.3 mmol/l and a GMI of 57.2 mmol/mol. There was a strong correlation between GMI and measured HbA1c (r We have shown here that the percentage glucose results above 18 mmol/l (top 5% of distribution) increased exponentially above 54 mmol/mol HbA1c. The %AVTD is introduced as a useful measure. Our data indicate that over the 24-h period, improvement in metabolic control could be focussed on the afternoon and evening, when there are higher-than-average levels of GMI, a higher-than-average degree of glucose change, and higher-than-average risks of being above the critical threshold. In conclusion, a measure of glycaemic variation based on the amplitude of glucose change to a population mean could be used to provide valuable clinical insights into glucose change over a 24-h period.
Identifiants
pubmed: 39443334
doi: 10.1007/s13300-024-01647-x
pii: 10.1007/s13300-024-01647-x
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. survival, causes of death, and complications. Diabetologia. 1978;14(6):363–70.
doi: 10.1007/BF01228130
pubmed: 669100
Diabetes Control and Complications Trial Research Group, Nathan DM. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.
doi: 10.1056/NEJM199309303291401
Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care. 2017;40:994–9.
doi: 10.2337/dc17-0636
pubmed: 28733374
pmcid: 5521971
Heinemann L, Freckmann G, Müller-Wieland D, Kellerer M. Critical reappraisal of the time-in-range: alternative or useful addition to glycated hemoglobin? J Diabetes Sci Technol. 2020;14(5):922–7.
doi: 10.1177/1932296819883885
pubmed: 31675907
Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–53.
doi: 10.1056/NEJMoa052187
pubmed: 16371630
The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968–83.
doi: 10.2337/diab.44.8.968
Kilpatrick ES, Rigby AS, Atkin SL. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care. 2009;32(10):1901–3.
doi: 10.2337/dc09-0109
pubmed: 19549736
pmcid: 2752912
Leelarathna L, Evans ML, Neupane S, Rayman G, Lumley S, Cranston I, Narendran P, Barnard-Kelly K, Sutton CJ, Elliott RA, Taxiarchi VP, Gkountouras G, Burns M, Mubita W, Kanumilli N, Camm M, Thabit H, Wilmot EG. Intermittently scanned continuous glucose monitoring for type 1 diabetes. N Engl J Med. 2022;387(16):1477–87.
doi: 10.1056/NEJMoa2205650
pubmed: 36198143
Bergenstal RM, Beck RW, Close KL, et al. Glucose Management Indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41(11):2275–80.
doi: 10.2337/dc18-1581
pubmed: 30224348
pmcid: 6196826
Gomez-Peralta F, Choudhary P, Cosson E, Irace C, Rami-Merhar B, Seibold A. Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin. Diabetes Obes Metab. 2022;24(4):599–608.
doi: 10.1111/dom.14638
pubmed: 34984825
Leelarathna L, Beck RW, Bergenstal RM, Thabit H, Hovorka R, APCam11, AP@home04 and APCam08 Investigators. Glucose management indicator (GMI): insights and validation using guardian 3 and navigator 2 sensor data. Diabetes Care. 2019;42(4):e60–1.
doi: 10.2337/dc18-2479
pubmed: 30728221
Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care. 2008;31(11):2198–202.
doi: 10.2337/dc08-0864
pubmed: 18650371
pmcid: 2571045
Virk SA, Donaghue KC, Cho YH, et al. Association between HbA1c variability and risk of microvascular complications in adolescents with type 1 diabetes. J Clin Endocrinol Metab. 2016;101(9):3257–63.
doi: 10.1210/jc.2015-3604
pubmed: 27186858
Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia. 2007;50:2553–61.
doi: 10.1007/s00125-007-0820-z
pubmed: 17882397
Toschi E, Slyne C, Sifre K, et al. The relationship between CGM-derived metrics, A1C, and risk of hypoglycemia in older adults with type 1 diabetes. Diabetes Care. 2020;43(10):2349–54.
doi: 10.2337/dc20-0016
pubmed: 32461211
pmcid: 7510030
Zhu J, Volkening LK, Laffel LM. Distinct patterns of daily glucose variability by pubertal status in youth with type 1 diabetes. Diabetes Care. 2020;43(1):22–8.
doi: 10.2337/dc19-0083
pubmed: 31308020
Biankin SA, Jenkins AB, Campbell LV, Choi KL, Forrest QG, Chisholm DJ. Target-seeking behavior of plasma glucose with exercise in type 1 diabetes. Diabetes Care. 2003;26(2):297–301.
doi: 10.2337/diacare.26.2.297
pubmed: 12547852
Montt-Blanchard D, Sánchez R, Dubois-Camacho K, Leppe J, Onetto MT. Hypoglycemia and glycemic variability of people with type 1 diabetes with lower and higher physical activity loads in free-living conditions using continuous subcutaneous insulin infusion with predictive low-glucose suspend system. BMJ Open Diabetes Res Care. 2023;11(2): e003082.
doi: 10.1136/bmjdrc-2022-003082
pubmed: 36944432
Al Kandari J, Al Ozairi E, Irshad M, Varghese A, Gray SR. Association of physical activity metrics with glucose variability in people with type 1 diabetes: A cross-sectional study. Eur J Sport Sci. 2024;24:210–6.
doi: 10.1002/ejsc.12062
pmcid: 11236049
Gorst C, Kwok CS, Aslam S, et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38(12):2354–69.
doi: 10.2337/dc15-1188
pubmed: 26604281
Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005;19(3):178–81.
doi: 10.1016/j.jdiacomp.2004.10.001
pubmed: 15866065
Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42(3):400–5.
doi: 10.2337/dc18-1444
pubmed: 30352896
Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631–40.
doi: 10.2337/dc17-1600
pubmed: 29162583
pmcid: 6467165
Ahola AJ, Mutter S, Forsblom C, et al. Meal timing, meal frequency, and breakfast skipping in adult individuals with type 1 diabetes – associations with glycaemic control. Sci Rep. 2019;9:20063.
doi: 10.1038/s41598-019-56541-5
pubmed: 31882789
pmcid: 6934661
Dutta D, Mohindra R, Mahajan K, Sharma M. Performance of fast-acting aspart insulin as compared to aspart insulin in insulin pump for managing type 1 diabetes mellitus: a meta-analysis. Diabetes Metab J. 2023;47(1):72–81.
doi: 10.4093/dmj.2022.0035
pubmed: 35746893
Russell-Jones D, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial. Diabetes Care. 2017;40(7):943–50.
doi: 10.2337/dc16-1771
pubmed: 28356319
Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018;391:1367–77.
doi: 10.1016/S0140-6736(18)30297-6
pubmed: 29459019
Breton MD, Patek SD, Lv D, et al. Continuous glucose monitoring and insulin informed advisory system with automated titration and dosing of insulin reduces glucose variability in type 1 diabetes mellitus. Diabetes Technol Ther. 2018;20:531–40.
doi: 10.1089/dia.2018.0079
pubmed: 29979618
pmcid: 6080127
Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R, Bolinder J. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia. 2017;61(539–550):201.
https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2019/07/dia-FreeStyle-Libre-training-pack-for-HCP-and-patients-052018.pdf : accessed 30 March 2024